Insiders · ACRS

ACRS insider transactions

Aclaris Therapeutics Inc. (ACRS) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for ACRS

• 3h
  Director Molineaux Christopher P. converted options into 11,580 shares, increasing direct ownership by 20% to 69,536 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 3h
  Director Milano Vincent converted options into 11,580 shares, increasing direct ownership by 67% to 28,896 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 3h
  Director Mehra Anand converted options into 11,580 shares, increasing direct ownership by 2% to 726,403 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 3h
  Director Humphries William D. converted options into 11,580 shares, increasing direct ownership by 35% to 45,105 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 3h
  Director Schiff Andrew N converted options into 11,580 shares, increasing direct ownership by 83% to 25,540 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 3h
  Director Gowen Maxine converted options into 11,580 shares, increasing direct ownership by 53% to 33,334 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 34d
  Chief Medical Officer Hall Jesse Wayne converted options into 36,375 shares and covered exercise/tax liability with 9,330 shares (SEC Form 4) to satisfy withholding tax

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 42d
  Large owner Leonard Braden Michael sold $1,359,000 worth of shares (300,000 units at $4.53) (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 97d
  Chief Financial Officer Balthaser Kevin converted options into 2,375 shares and covered exercise/tax liability with 677 shares, increasing direct ownership by 0.91% to 187,453 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 122d
  SEC Form 4 filed by CEO Walker Neal

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 122d
  SEC Form 4 filed by President and COO Davis Hugh M.

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 122d
  SEC Form 4 filed by Chief Scientific Officer Kolbeck Roland Wilhelm

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 122d
  SEC Form 4 filed by Chief Medical Officer Hall Jesse Wayne

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 122d
  SEC Form 4 filed by Chief Business Officer Loerop James

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 122d
  SEC Form 4 filed by Chief Financial Officer Balthaser Kevin

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 123d
  Chief Business Officer Loerop James converted options into 20,875 shares and covered exercise/tax liability with 5,937 shares, increasing direct ownership by 8% to 192,260 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 123d
  CEO Walker Neal converted options into 63,475 shares and covered exercise/tax liability with 18,611 shares, increasing direct ownership by 3% to 1,543,886 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 123d
  President and COO Davis Hugh M. converted options into 18,675 shares, increasing direct ownership by 70% to 45,425 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 123d
  Chief Financial Officer Balthaser Kevin converted options into 22,025 shares and covered exercise/tax liability with 6,449 shares, increasing direct ownership by 9% to 185,755 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 123d
  Amendment: Chief Business Officer Loerop James converted options into 33,500 shares and covered exercise/tax liability with 10,686 shares, increasing direct ownership by 15% to 177,322 units (SEC Form 4)

  4/A - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 125d
  Chief Financial Officer Balthaser Kevin covered exercise/tax liability with 4,984 shares and converted options into 14,750 shares, increasing direct ownership by 6% to 170,179 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 125d
  Chief Business Officer Loerop James covered exercise/tax liability with 15,980 shares, decreasing direct ownership by 13% to 102,773 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 125d
  Amendment: Chief Business Officer Loerop James covered exercise/tax liability with 15,980 shares, decreasing direct ownership by 13% to 102,773 units (SEC Form 4)

  4/A - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 154d
  CEO Walker Neal converted options into 29,150 shares and covered exercise/tax liability with 9,952 shares, increasing direct ownership by 1% to 1,499,022 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 154d
  Chief Business Officer Loerop James converted options into 91,900 shares and covered exercise/tax liability with 40,165 shares, increasing direct ownership by 50% to 155,041 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 154d
  Chief Financial Officer Balthaser Kevin converted options into 94,450 shares and covered exercise/tax liability with 26,645 shares, increasing direct ownership by 73% to 160,413 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 186d
  President and COO Davis Hugh M. converted options into 26,750 shares (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 307d
  SEC Form 4 filed by Chief Scientific Officer Kolbeck Roland Wilhelm

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 307d
  SEC Form 3 filed by new insider Kolbeck Roland Wilhelm

  3 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 364d
  Director Milano Vincent converted options into 4,793 shares, increasing direct ownership by 38% to 17,316 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 364d
  Director Mehra Anand converted options into 4,793 shares, increasing direct ownership by 0.68% to 714,823 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 364d
  Director Schiff Andrew N converted options into 4,793 shares, increasing direct ownership by 52% to 13,960 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 364d
  Director Humphries William D. converted options into 4,793 shares, increasing direct ownership by 17% to 33,525 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 364d
  Director Gowen Maxine converted options into 4,793 shares, increasing direct ownership by 28% to 21,754 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 364d
  Director Molineaux Christopher P. converted options into 4,793 shares, increasing direct ownership by 9% to 57,956 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 399d
  SEC Form 4 filed by Chief Medical Officer Hall Jesse Wayne

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 399d
  SEC Form 3 filed by new insider Hall Jesse Wayne

  3 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 399d
  CEO Walker Neal converted options into 9,467 shares and covered exercise/tax liability with 2,975 shares, increasing direct ownership by 0.44% to 1,479,824 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 431d
  CEO Walker Neal converted options into 9,467 shares and covered exercise/tax liability with 3,042 shares, increasing direct ownership by 0.44% to 1,473,332 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 461d
  Chief Financial Officer Balthaser Kevin converted options into 3,475 shares and covered exercise/tax liability with 727 shares, increasing direct ownership by 3% to 92,608 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 461d
  Chief Scientific Officer Monahan Joseph converted options into 60,925 shares and covered exercise/tax liability with 27,258 shares, increasing direct ownership by 15% to 265,662 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 461d
  CEO Walker Neal covered exercise/tax liability with 3,277 shares and converted options into 9,466 shares, increasing direct ownership by 0.42% to 1,466,907 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 489d
  Chief Scientific Officer Monahan Joseph converted options into 22,250 shares and covered exercise/tax liability with 11,317 shares, increasing direct ownership by 5% to 231,995 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 489d
  INTERIM CEO Walker Neal converted options into 9,467 shares and covered exercise/tax liability with 3,559 shares, increasing direct ownership by 0.41% to 1,460,718 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 489d
  SEC Form 4 filed by President and COO Davis Hugh M.

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 489d
  Chief Financial Officer Balthaser Kevin converted options into 14,750 shares and covered exercise/tax liability with 5,816 shares, increasing direct ownership by 11% to 89,860 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 489d
  Chief Business Officer Loerop James converted options into 33,500 shares and covered exercise/tax liability with 15,447 shares, increasing direct ownership by 21% to 103,306 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 521d
  Chief Financial Officer Balthaser Kevin converted options into 94,450 shares and covered exercise/tax liability with 38,221 shares, increasing direct ownership by 228% to 80,926 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 521d
  INTERIM CEO Walker Neal converted options into 38,616 shares and covered exercise/tax liability with 17,436 shares, increasing direct ownership by 1% to 1,454,810 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 521d
  Chief Business Officer Loerop James converted options into 91,900 shares and covered exercise/tax liability with 40,664 shares, increasing direct ownership by 151% to 85,253 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 521d
  Chief Scientific Officer Monahan Joseph converted options into 91,130 shares and covered exercise/tax liability with 41,851 shares, increasing direct ownership by 29% to 221,062 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 543d
  Chief Scientific Officer Monahan Joseph gifted 15,000 shares, decreasing direct ownership by 8% to 171,783 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 549d
  INTERIM CEO Walker Neal exercised 118,840 shares at a strike of $1.52 and covered exercise/tax liability with 68,343 shares, increasing direct ownership by 4% to 1,433,630 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 552d
  SEC Form 4 filed by President and COO Davis Hugh M.

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 552d
  INTERIM CEO Walker Neal converted options into 9,466 shares and covered exercise/tax liability with 2,721 shares, increasing direct ownership by 0.49% to 1,383,133 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 560d
  SEC Form 3 filed by new insider Biosion, Inc.

  3 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 565d
  Director Mehra Anand bought $1,499,998 worth of shares (666,666 units at $2.25), increasing direct ownership by 1,537% to 710,030 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 567d
  SEC Form 3 filed by new insider Davis Hugh M.

  3 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 580d
  INTERIM PRESIDENT AND CEO Walker Neal converted options into 9,467 shares and covered exercise/tax liability with 2,721 shares, increasing direct ownership by 0.49% to 1,376,388 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
• 613d
  INTERIM PRESIDENT AND CEO Walker Neal converted options into 9,467 shares and covered exercise/tax liability with 2,722 shares, increasing direct ownership by 0.49% to 1,369,642 units (SEC Form 4)

  4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)